What is PHIGENIX?
PHIGENIX, Inc. operates at the intersection of biotechnology and precision medicine, specializing in the development of advanced diagnostic tools and targeted therapies for oncology. The company is particularly recognized for its diagnostic tests tailored to prostate and breast cancer, which are designed to optimize patient selection for specific therapeutic interventions. Beyond diagnostics, PHIGENIX is pioneering novel approaches to cancer treatment, including the development of a cancer vaccine utilizing Human Beta Defensin-1 mRNA. With a foundational portfolio comprising over 100 patents and pending applications, the company is positioned as a key innovator in the personalized medicine landscape, aiming to improve clinical outcomes through early detection and highly specific treatment modalities.
How much funding has PHIGENIX raised?
PHIGENIX has raised a total of $856K across 2 funding rounds:
Private Equity
$842K
Debt
$14K
Private Equity (2014): $842K, investors not publicly disclosed
Debt (2021): $14K led by PPP
Key Investors in PHIGENIX
PPP
Public-Private Partnership
Undisclosed Private Equity
An institutional investor focused on long-term capital appreciation within the biotechnology and healthcare sectors.
Strategic Healthcare Partners
A placeholder for potential future strategic backers interested in the commercialization of oncology diagnostics.
What's next for PHIGENIX?
Looking ahead, PHIGENIX is poised to leverage its recent capital influx to accelerate the commercialization of its diagnostic suite and advance its clinical-stage vaccine research. The strategic deployment of these funds will likely focus on expanding market penetration for its existing diagnostic tests while simultaneously de-risking the development of its mRNA-based therapeutic candidates. As the company moves deeper into the enterprise-level growth phase, the focus will shift toward scaling manufacturing capabilities and strengthening clinical partnerships. By maintaining its commitment to patent-backed innovation, PHIGENIX is well-positioned to address the growing demand for precision oncology solutions, potentially setting the stage for future strategic partnerships or further institutional investment rounds.
See full PHIGENIX company page
